Among 487,521 UK Biobank participants with NMR metabolomics profiling, an overabundance of small and medium LDL particles (S/M LDL-P) beyond what standard LDL-C levels would predict — termed S/M LDL-P discordance — independently raised major adverse cardiovascular event (MACE) risk. In 47,935 cases, each standard deviation of discordance elevated MACE hazard by 9% in metabolically healthy individuals and by 24% in those with high cardiometabolic burden, independent of both LDL-C and ApoB. Loss-of-function variants in CETP, a protein governing cholesterol-triglyceride exchange, dramatically reduced S/M LDL-P discordance, particularly in high-burden individuals (−11.10 nmol/L vs. −4.62 nmol/L in low-burden).
This large-scale finding challenges the adequacy of standard lipid panels for cardiovascular risk stratification. Decades of clinical practice have relied on LDL-C, and more recently ApoB, as proxies for atherogenic burden — yet both may systematically undercount risk in people with diabetes, obesity, or insulin resistance, precisely where small dense LDL particles proliferate. The CETP genetic data add a compelling mechanistic layer: CETP inhibition, long controversial after high-profile drug failures, may derive cardiovascular benefit partly through LDL particle remodeling rather than HDL elevation alone. This could rehabilitate CETP as a therapeutic target with a better-defined mechanism. Limitations include the observational design, the predominantly European UK Biobank cohort limiting generalizability, and the cross-sectional NMR measurement. As a preprint not yet peer-reviewed, these findings require independent replication before influencing clinical lipid guidelines.
